PMID- 31746482
OWN - NLM
STAT- MEDLINE
DCOM- 20200727
LR  - 20200727
IS  - 1365-2036 (Electronic)
IS  - 0269-2813 (Linking)
VI  - 51
IP  - 2
DP  - 2020 Jan
TI  - Systematic review: chronic viral hepatitis and metabolic derangement.
PG  - 216-230
LID - 10.1111/apt.15575 [doi]
AB  - BACKGROUND: The liver has a critical role in the metabolism of glucose and 
      lipids. Chronic hepatitis B virus (HBV) or hepatitis C virus (HCV) infection 
      leads to a spectrum of liver disease including chronic hepatitis, cirrhosis and 
      hepatocellular carcinoma. Metabolic syndrome (MetS) has a rising incidence owing 
      to an epidemic of type 2 diabetes mellitus (T2DM) and obesity. Non-alcoholic 
      fatty liver disease is a liver manifestation of MetS and has become the most 
      common cause of chronic liver disease worldwide. AIM: To summarise the interplay 
      among hepatitis viruses, MetS and its components. METHODS: We searched the 
      literature about HBV, HCV infection, MetS, fatty liver and its components from 
      PubMed. RESULTS: With respect to the viral replication cycle, lipids are 
      important mediators between viral entry and hepatocyte in HCV infection, but not 
      in HBV infection. Thus, HCV infection is inversely associated with 
      hyperlipidaemia and lipid rebound occurs following sustained viral response 
      induced by interferon-based therapy or direct antiviral agents. In addition, HCV 
      infection is positively associated with insulin resistance, hepatic steatosis, 
      MetS and the risk of T2DM and atherosclerosis. In contrast, HBV infection may 
      protect infected subjects from the development of MetS and hepatic steatosis. 
      Accumulating evidence suggests that HBV infection is inversely associated with 
      lipid metabolism, and exhibits no conclusive association with insulin resistance 
      or the risk of T2DM and arteriosclerosis. CONCLUSIONS: In patients with viral 
      hepatitis and concurrent metabolic diseases, a multidisciplinary approach should 
      be given rather than simply antiviral treatment.
CI  - (c) 2019 John Wiley & Sons Ltd.
FAU - Wang, Chia-Chi
AU  - Wang CC
AUID- ORCID: 0000-0002-0827-4503
AD  - Department of Gastroenterology and Hepatology, Buddhist Tzu Chi Medical 
      Foundation and School of Medicine, Taipei Tzu Chi Hospital, Tzu Chi University, 
      Hualien, Taiwan.
FAU - Cheng, Pin-Nan
AU  - Cheng PN
AD  - Department of Internal Medicine, College of Medicine, National Cheng Kung 
      University Hospital, National Cheng Kung University, Tainan, Taiwan.
FAU - Kao, Jia-Horng
AU  - Kao JH
AUID- ORCID: 0000-0002-2442-7952
AD  - Graduate Institute of Clinical Medicine, National Taiwan University College of 
      Medicine, Taipei, Taiwan.
AD  - Department of Internal Medicine, Department of Medical Research and Hepatitis 
      Research Center, National Taiwan University Hospital, Taipei, Taiwan.
LA  - eng
PT  - Journal Article
PT  - Systematic Review
DEP - 20191120
PL  - England
TA  - Aliment Pharmacol Ther
JT  - Alimentary pharmacology & therapeutics
JID - 8707234
RN  - 0 (Antiviral Agents)
SB  - IM
MH  - Antiviral Agents/therapeutic use
MH  - Carcinoma, Hepatocellular/epidemiology/therapy/virology
MH  - Diabetes Mellitus, Type 2/complications/epidemiology
MH  - Hepacivirus/physiology
MH  - Hepatitis B, Chronic/*complications/epidemiology/metabolism/therapy
MH  - Hepatitis C, Chronic/*complications/epidemiology/metabolism/therapy
MH  - Humans
MH  - Incidence
MH  - Liver Cirrhosis/epidemiology/therapy/virology
MH  - Liver Neoplasms/epidemiology/therapy/virology
MH  - Metabolic Diseases/epidemiology/*etiology/metabolism/therapy
MH  - Metabolic Syndrome/epidemiology/therapy/virology
MH  - Non-alcoholic Fatty Liver Disease/epidemiology/therapy/virology
MH  - Obesity/epidemiology/therapy/virology
EDAT- 2019/11/21 06:00
MHDA- 2020/07/28 06:00
CRDT- 2019/11/21 06:00
PHST- 2019/06/30 00:00 [received]
PHST- 2019/08/08 00:00 [revised]
PHST- 2019/10/17 00:00 [accepted]
PHST- 2019/11/21 06:00 [pubmed]
PHST- 2020/07/28 06:00 [medline]
PHST- 2019/11/21 06:00 [entrez]
AID - 10.1111/apt.15575 [doi]
PST - ppublish
SO  - Aliment Pharmacol Ther. 2020 Jan;51(2):216-230. doi: 10.1111/apt.15575. Epub 2019 
      Nov 20.